ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective

There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research...

Descripción completa

Detalles Bibliográficos
Autores principales: Koessler, T., Alsina, M., Arnold, D., Ben-Aharon, I., Collienne, M., Lutz, M.P., Neuzillet, C., Obermannova, R., Peeters, M., Sclafani, F., Smyth, E., Valle, J.W., Wagner, A.D., Wyrwicz, L., Fontana, E., Moehler, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857487/
https://www.ncbi.nlm.nih.gov/pubmed/35180656
http://dx.doi.org/10.1016/j.esmoop.2022.100392
Descripción
Sumario:There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

Ejemplares similares